QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
May 23, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, May 23, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for...
QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 08:00 ET
|
QSAM Biosciences Inc.
Dosed First Patient in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer Austin, TX, May 17, 2022 (GLOBE NEWSWIRE) -- QSAM...